AD/PD 2021: Unlearn will present novel, AI-driven approaches to enabling smaller, more efficient Alzheimer’s clinical trials

Join us at The 15th​ International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders, March 9 - 14, 2021. AD/PD 2021 is a virtual conference that covers the most recent research, clinical trials, developments, and treatments in Alzheimer’s and Parkinson’s, providing unparalleled and powerful insights into these devastating neurodegenerative diseases. 

Our oral presentation, entitled Digital Twins enable smaller trials that maintain their power: A Demonstration for Alzheimer’s Drug Trials (1066), will take place in the session Digital End-Points and Artificial Intelligence. In this presentation, Unlearn data scientist Alejandro Schuler, PhD, will describe how Digital Twins leverage historical data, covariate adjustment, and machine learning to reduce the size of trials while maintaining power and control of false positives. This presentation will be available on-demand throughout the conference. A live Q&A Discussion for the session Digital End-Points and Artificial Intelligence will be held on Sunday, March 14, from 17:30 - 18:00 CET, Barcelona (8:30am - 9am PST). 

Our Founder and CEO, Charles Fisher, PhD, will be featured as one of five panelists in the live forum discussion Phase I-II Clinical Trials In Alzheimer’s Disease, co-moderated by world-renowned AD researchers and clinical trial leaders Jeffrey Cummings and Manfred Windisch, on Thursday, 03/11/2021, 18:30 - 19:30 CET - Barcelona (9:30am - 10:30am PST).

In addition to presenting and attending sessions, Unlearn team members will be readily available to connect throughout the conference. Reach out to us via the AD/PD 2021 event platform, or at partnerships@unlearn.ai to schedule a time to meet with us to discuss how Digital Twins can accelerate your clinical research. 

We invite you to participate in AD/PD 2021, as we continue to build upon our collective knowledge of Alzheimer’s, Parkinson’s and other related neurodegenerative diseases. The more data we share, the more effective we will be in developing and delivering more effective prevention and treatment options for patients.

Enter your email address to download paper.

Click the link to begin download.
Oops! Something went wrong while submitting the form.
White Papers

Applications of Digital Twins in Clinical Trials for Alzheimer’s Disease

Press

Unlearn.AI named to the 2021 CB Insights AI 100 List of Most Innovative Artificial Intelligence Startups

Blog

Welcoming Dr. Taylor to Unlearn.AI’s Board of Directors

I’m honored to have such an inspirational and experienced leader like Dr. Taylor join our board.
The AI 100 is CB Insights' annual list of the 100 most promising private AI companies in the world.
How Digital Twins make it possible to design and run more efficient clinical trials with well-defined statistical properties.